Benitec Biopharma Reports $8.965 Million Net Loss and No Revenue for Q3 2025

Benitec Biopharma Inc. reported a net loss of $8.965 million for the three months ended September 30, 2025, compared to a net loss of $5.059 million for the same period in 2024. The company did not generate any revenue during this quarter, maintaining a consistent trend from the previous year. Total operating expenses increased significantly to $9.803 million, up from $5.791 million in the prior year, primarily driven by a rise in general and administrative expenses, which surged to $6.433 million from $2.206 million. This increase was largely attributed to a $4 million rise in share-based compensation and additional salary expenses.

In terms of operational metrics, Benitec's research and development expenses decreased slightly to $3.370 million from $3.585 million year-over-year, reflecting the timing of contract manufacturing activities and payments related to ongoing clinical studies. The company continues to focus on the development of its lead product candidate, BB-301, aimed at treating Oculopharyngeal Muscular Dystrophy (OPMD). The investigational new drug application for BB-301 was approved by the U.S. FDA in June 2023, and the company has initiated a Phase 1b/2a clinical trial, with positive interim results reported in November 2025.

As of September 30, 2025, Benitec had cash and cash equivalents totaling approximately $94.5 million, a decrease from $97.9 million at the end of the previous fiscal quarter. The company did not engage in any financing activities during the quarter, contrasting with the $21.7 million raised in the same period last year through the exercise of warrants. The company’s liquidity position is expected to support its operations for at least the next twelve months, although it remains dependent on future capital financing to fund ongoing development activities.

Benitec's strategic focus includes advancing its proprietary "silence and replace" technology, which combines RNA interference with gene therapy to address genetic disorders. The company has not yet established a source of revenue from product sales and anticipates continued operating losses as it progresses through clinical trials. The management remains optimistic about the potential of BB-301 and its ability to generate significant revenue upon successful commercialization, although no assurances can be made regarding the timing or success of these efforts.

Looking ahead, Benitec plans to continue its clinical development of BB-301 while exploring partnerships and collaborations to enhance its market position. The company is also evaluating opportunities for additional financing to support its growth and operational needs. The ongoing development of BB-301, along with the potential for future product candidates, positions Benitec to address significant unmet medical needs in the genetic medicine space.